Severe asthma exacerbations, proportion of patients (%) | |||||
Trial | Background medication | Tiotropium Respimat® 5 µg | Placebo Respimat® | HRa (95% CI) | p value |
PrimoTinA-asthma®b | ICS + LABA (>800 μg budesonide or equivalent) | 122/453 (26.9) | 149/454 (32.8) | 0.79 (0.62, 1.00) | 0.034 |
MezzoTinA-asthma®c | ICS (400–800 µg budesonide or equivalent) | 31/513 (6.0) | 43/518 (8.3) | 0.72 (0.45, 1.14) | 0.164 |
GraziaTinA-asthma®d | ICS (200–400 µg budesonide or equivalent) | 1/151 (0.7) | 4/151 (2.6) | 0.25 (0.03, 2.24) | 0.216 |
↵aHazard ratio, time to first severe exacerbation (vs placebo, <1 favours tiotropium Respimat®); bBaseline to Week 48, NCT00776984/NCT00772538; cBaseline to Week 24, NCT01172808/NCT01172821; dBaseline to time of last event, NCT01316380.